Merck: Lung Cancer Lead Depends On “How Smart It Plays Its Hand”

With billions of dollars in drug sales at stake, the battled between Merck & Co . ( MRK ) and Bristol-Myers Squibb ( BMY ) over which company's new lung cancer drug will dominate is far from settled. For now, it looks like Merck is sitting in the cat bird’s seat. But whether it remains there depends “how smart Merck plays its hand," says Bernstein analyst Tim Anderson.